Mural Oncology PLC

Mural Oncology plc has completed its acquisition by XOMA Royalty Corporation subsidiary, XRA 5 Corp., with shareholders receiving $2.035 per share in cash.

Mural Oncology plc shareholders overwhelmingly approved the proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, paving the way for completion in Q4 2025.

Mural Oncology plc has entered into a definitive agreement to be acquired by XOMA Royalty Corporation for a cash consideration of $2.035 to $2.24 per share, following Mural's decision to discontinue all clinical development.

Mural Oncology reported a wider net loss in Q2 2025, driven by restructuring charges, as it continues to explore strategic alternatives after discontinuing all clinical development programs.

Mural Oncology plc announced the successful re-election of all six director nominees and the ratification of PricewaterhouseCoopers LLP as its independent auditor at its 2025 Annual General Meeting.

Mural Oncology discontinues clinical development of nemvaleukin alfa, reduces workforce by 90%, and explores strategic alternatives to maximize shareholder value.

Mural Oncology plc reports Q3 2025 results amidst a pending acquisition by XOMA Royalty Corporation, following the discontinuation of all clinical and preclinical development programs.

Mural Oncology plc has discontinued all clinical and preclinical development, initiated a strategic review, and faces substantial doubt about its ability to continue as a going concern.

Mural Oncology discontinues clinical development of nemvaleukin and initiates exploration of strategic alternatives following disappointing Phase 3 trial results.

Mural Oncology's Q3 2024 report details ongoing clinical trials, financial results, and operational updates following its separation from Alkermes plc.

Mural Oncology's second quarter 2024 results show a net loss of $31.6 million, with ongoing clinical trials for their lead product candidate, nemvaleukin.

Mural Oncology's first quarter 2024 results show a net loss of $30.9 million, with ongoing clinical trials and a focus on advancing their immunotherapy pipeline.

Mural Oncology's 10-K filing highlights financial uncertainties regarding its ability to continue as a going concern, despite ongoing clinical trials for its lead product candidate, nemvaleukin alfa, and other pipeline developments.

Mural Oncology's 10-K filing outlines its capital structure, share issuance policies, dividend procedures, and compliance with Irish and U.S. securities regulations.

Mural Oncology plc Director Benjamin Hickey's stock options were cancelled without consideration following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Mural Oncology plc's CEO, Caroline Loew, disposed of her beneficial ownership in ordinary shares and stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Mural Oncology plc director Francis M. Cuss reports the cancellation of stock options following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Mural Oncology plc director Scott Thomas Jackson's stock options were cancelled following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Mural Oncology plc has been acquired by XRA 5 Corp. for $2.035 per share, resulting in the cancellation of certain stock options without consideration.

Mural Oncology plc director Sachiyo Minegishi's stock options were cancelled without consideration following the company's acquisition by XRA 5 Corp. for $2.035 per share.

Mural Oncology plc reminds shareholders to vote on proposals for both the Scheme Meeting and Extraordinary General Meeting by October 23, 2025, concerning an acquisition.

Mural Oncology plc shareholders are set to vote on October 24, 2025, on the proposed acquisition by XRA 5 Corp, a subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Mural Oncology plc announces the publication of the Rule 15 Proposal and definitive proxy statement related to its acquisition by XOMA Royalty Corporation for cash.

Mural Oncology plc details the treatment of equity awards for its proposed acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, for a cash consideration of $2.035 to $2.24 per share.

Mural Oncology plc has commenced mailing its definitive proxy statement to shareholders regarding the acquisition by XOMA Royalty Corporation via a scheme of arrangement.

Mural Oncology plc shareholders to vote on a scheme of arrangement for acquisition by XOMA Royalty Corporation, offering $2.035 to $2.24 per share in cash.

Trium Capital LLP has filed an amended Schedule 13G, reporting a complete divestment of its beneficial ownership in Mural Oncology plc, now holding 0% of the ordinary shares.

Prosight Management and its affiliated funds have fully divested their beneficial ownership in Mural Oncology plc, reporting a 0% stake.

Soleus Capital Master Fund and its affiliates have reported a complete divestment of their beneficial ownership in Mural Oncology plc, now holding 0% of the company's ordinary shares.

Trium Capital LLP, a UK-based investment adviser, has reported a 10.16% beneficial ownership stake in Mural Oncology plc.

Armistice Capital and Steven Boyd have filed an amended Schedule 13G, reporting zero beneficial ownership in Mural Oncology plc's ordinary shares.

Solas Capital Management and Frederick Tucker Golden have fully divested their beneficial ownership in Mural Oncology plc, now holding 0% of ordinary shares.